RS51195B - Upotreba visoko koncentrovanih kompozicija odabranih n-3-masnih kiselina za lečenje poremećaja centralnog nervnog sistema - Google Patents

Upotreba visoko koncentrovanih kompozicija odabranih n-3-masnih kiselina za lečenje poremećaja centralnog nervnog sistema

Info

Publication number
RS51195B
RS51195B RSP-2009/0437A RSP20090437A RS51195B RS 51195 B RS51195 B RS 51195B RS P20090437 A RSP20090437 A RS P20090437A RS 51195 B RS51195 B RS 51195B
Authority
RS
Serbia
Prior art keywords
epa
ethyl ester
dha
treatment
nervous system
Prior art date
Application number
RSP-2009/0437A
Other languages
English (en)
Inventor
Tiberio Bruzzese
Original Assignee
Tiberio Bruzzese
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34803698&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51195(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tiberio Bruzzese filed Critical Tiberio Bruzzese
Publication of RS51195B publication Critical patent/RS51195B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Upotreba kompozicije koja sadrži u koncentraciji izraženoj kao tež. % ukupne težine masnih kiselina u kompoziciji, ilia) DHA etil estar >34 i EPA etil estar >40, pri čemu su EPA+DHA etil estri >85, ilib) DHA etil estar >30 i EPA etil estar >44, pri čemu su EPA+DHA etil estri >80, etil estri drugih (C20, C21, C22) n-3 kiselina su >3, ili c) DHA etil estar >34 i EPA etil estar >40, pri čemu su EPA+DHA etil estri >80, ukupni etil estari n-3 kiselina su >90, ilid) DHA etil estar >80 i EPA etil estar <15, pri čemu su EPA+DHA etil estri >85,za dobijanje leka za prevenciju i/ili lečenje psihijatrijskih poremećaja centralnog nervnog sistema (CNS) odabrani od šizofrenije, manično-depresivnog sindroma, velike depresije, i Alzheimer'ove bolesti.Prijava sadrži još 13 zavisnih patentnih zahteva.
RSP-2009/0437A 2004-01-21 2005-01-20 Upotreba visoko koncentrovanih kompozicija odabranih n-3-masnih kiselina za lečenje poremećaja centralnog nervnog sistema RS51195B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000069A ITMI20040069A1 (it) 2004-01-21 2004-01-21 Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
PCT/EP2005/000522 WO2005070411A1 (en) 2004-01-21 2005-01-20 USE OF HIGHLY CONCENTRATED COMPOSITIONS OF SELECTED n-3 FATTY ACIDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES

Publications (1)

Publication Number Publication Date
RS51195B true RS51195B (sr) 2010-10-31

Family

ID=34803698

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0437A RS51195B (sr) 2004-01-21 2005-01-20 Upotreba visoko koncentrovanih kompozicija odabranih n-3-masnih kiselina za lečenje poremećaja centralnog nervnog sistema

Country Status (12)

Country Link
US (1) US8829048B2 (sr)
EP (1) EP1706106B9 (sr)
JP (1) JP5087280B2 (sr)
DE (1) DE602005015415D1 (sr)
DK (1) DK1706106T3 (sr)
ES (1) ES2329809T3 (sr)
HR (1) HRP20090550T1 (sr)
IT (1) ITMI20040069A1 (sr)
PL (1) PL1706106T3 (sr)
PT (1) PT1706106E (sr)
RS (1) RS51195B (sr)
WO (1) WO2005070411A1 (sr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252742B2 (en) * 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
EP1968567B1 (en) 2005-12-20 2014-06-18 Cenestra, Llc Omega 3 fatty acid formulations
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
AU2006327064B2 (en) 2005-12-21 2012-04-26 Brudy Technology, S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
EP2612672A1 (en) 2007-03-28 2013-07-10 Aker BioMarine AS Bioeffective krill oil compositions
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CA2773031C (en) 2008-09-09 2021-03-02 Orygen Youth Health Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
WO2012083034A1 (en) * 2010-12-15 2012-06-21 Louis Sanfilippo Modulation of neurotrophic factors by omega-3 fatty acid formulations
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
KR102079747B1 (ko) 2015-02-11 2020-02-20 에이커 바이오마린 앤탁틱 에이에스 지질 조성물
PT3256003T (pt) 2015-02-11 2023-02-15 Aker Biomarine Antarctic As Processo de extração de lipídios
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
PL238670B1 (pl) * 2018-07-06 2021-09-20 Skotan Spolka Akcyjna Sposób otrzymywania oczyszczonej kompozycji estrów kwasów tłuszczowych i kompozycja estrów kwasów tłuszczowych
JPWO2022050355A1 (sr) * 2020-09-04 2022-03-10

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
GB8601915D0 (en) 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
IT1205043B (it) * 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
DE3739700A1 (de) * 1987-11-24 1989-06-08 Guenther Dr Med Jeschke Alpha-linolensaeure (18:3,omega 3) und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung und anwendung in ernaehrung und medizin
JP2524217B2 (ja) 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
GB2218904A (en) 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
GB2218984B (en) 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FR2688145B1 (fr) 1992-03-06 1994-09-23 Borden France Sa Procede et installation pour separer un effluent sous forme de vapeur d'un courant de gaz vecteur.
JPH0672868A (ja) * 1992-08-26 1994-03-15 Maruha Corp 抗精神病薬
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
DE69720787T2 (de) * 1996-10-11 2004-03-18 Scarista Ltd., Douglas Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
DE60022987T2 (de) 2000-05-22 2006-10-19 Pro Aparts - Investimentos E Consultoria Lda., Funchal Fettsäurezusammensetzung, die wenigstens 80 Gew.-% EPA und DHA enthält
IT1320180B1 (it) 2000-12-29 2003-11-26 Hunza Di Marazzita Maria Carme Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods

Also Published As

Publication number Publication date
ES2329809T3 (es) 2009-12-01
PL1706106T3 (pl) 2009-12-31
HRP20090550T1 (hr) 2010-01-31
JP2007518764A (ja) 2007-07-12
DE602005015415D1 (de) 2009-08-27
US20070161705A1 (en) 2007-07-12
EP1706106A1 (en) 2006-10-04
EP1706106B9 (en) 2009-09-16
DK1706106T3 (da) 2009-10-12
PT1706106E (pt) 2009-09-04
US8829048B2 (en) 2014-09-09
EP1706106B1 (en) 2009-07-15
JP5087280B2 (ja) 2012-12-05
ITMI20040069A1 (it) 2004-04-21
WO2005070411A1 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
RS51195B (sr) Upotreba visoko koncentrovanih kompozicija odabranih n-3-masnih kiselina za lečenje poremećaja centralnog nervnog sistema
FR2860976B1 (fr) Nouvelles compositions synergiques pour ameliorer la biodisponibilite et l&#39;efficacite des acides gras polyinsatures pour le traitement des troubles du fonctionnement cerebral.
PH12014502412A1 (en) Use of dpa (n-6) oils in infant formula
BR0011448A (pt) Imidazoquinolinas substituìdas por amida
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d&#39;utilisation associés
WO2007117511A3 (en) Feed formulations containing docosahexaenoic acid
MY153979A (en) Substituted piperidino-dihydrothienopyrimidine
DK1157692T3 (da) Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
DE60227951D1 (de) Delta-4-desaturase-gene und ihre verwendung
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
ATE456645T1 (de) Funktionelle acylglyceride
ECSP088499A (es) Nuevos compuestos de 2-amino-imidazol-4-ona y su uso en la fabricación de un medicamento para uso en el tratamiento de alteración cognitiva, enfermedad de alzheimer, neurodegeneración y demencia
FR2878747B1 (fr) Utilisation d&#39;acide(s) gras omega-3 pour le traitement de l&#39;hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
MA27518A1 (fr) Nouveau procede de synthese et nouvelle forme cristalline de l&#39;agomelatine ainsi que les compositions pharmaceutiques qui la contiennent
DE69522947D1 (en) Phenylxanthin-derivate
NO20090692L (no) Farmasoytiske og kostholdsprodukter som omfatter vitamin K2
JP2007518764A5 (sr)
IL190710A0 (en) Diuretic-like compound analogs and pharmaceutical compositions for regulation of central nervous system disorders containing the same
GEP20104959B (en) Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
ATE491446T1 (de) Ligustilid zur behandlung von erkrankungen des zentralen nervensystems
EA200500173A1 (ru) Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
MA32781B1 (fr) Arycyclohexylethers de dihydrotetrazabenzoazulenes pour emploi en tant qu&#39;antagonistes du recepteur v1a de la vasopressine
ATE516339T1 (de) Verwendung von isomeren von bicycloä2.2.1ühept-5- en-2-carbonsäure, ethylester in parfumzusammensetzungen, sowie parfumzusammensetzungen
MX2009004339A (es) Alcoholes de acido graso.
RU2006103804A (ru) Антиоксидантная жировая или масляная композиция, содержащая высоконенасыщенную длинноцепьевую жирную кислоту